Amneal Pharmaceuticals, Inc. AMRX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $282.03M+155% | $110.55M+20.8% | $91.54M+252% | $25.98M-89.5% | ||
| $10.34M-63.9% | $28.61M+137% | -$77.23M-110% | $741.79M+12.0% | ||
| $606.3M-1.0% | $612.45M+5.3% | $581.38M+9.5% | $530.74M+8.4% | ||
| $1.91B+20.4% | $1.59B+15.2% | $1.38B-2.4% | $1.41B-7.1% | ||
| $442.95M+4.2% | $424.91M-5.1% | $447.57M-4.7% | $469.82M-8.6% | ||
| $595.47M-0.3% | $597.44M-0.2% | $598.63M0.0% | $598.85M+1.0% | ||
| $563.5M-23.1% | $732.38M-17.7% | $890.42M-18.8% | $1.1B-6.1% | ||
| $3.68B+5.1% | $3.5B+0.8% | $3.47B-8.6% | $3.8B-3.6% | ||
| $6.76M-97.0% | $224.21M+557% | $34.13M+13.9% | $29.96M-2.1% | ||
| $881.63M-22.0% | $1.13B+33.4% | $846.6M+12.5% | $752.8M+11.2% | ||
| $2.57B+18.7% | $2.16B-9.4% | $2.39B-7.9% | $2.59B-3.3% | ||
| $2.79B+15.5% | $2.42B-5.8% | $2.56B-9.6% | $2.84B-1.4% | ||
| —— | —— | —— | —— | ||
| -$535.01M+11.9% | -$607.06M-23.8% | -$490.18M-20.7% | -$406.18M-47.1% | ||
| -$70.79M+35.2% | -$109.27M-652% | $19.78M-93.4% | $298.42M-17.2% | ||
| $3.68B+5.1% | $3.5B+0.8% | $3.47B-8.6% | $3.8B-3.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Amneal Pharmaceuticals, Inc.'s total assets?
- Amneal Pharmaceuticals, Inc. (AMRX) holds $3.5B in total assets, up 5.2% year over year.
- How much debt does Amneal Pharmaceuticals, Inc. have?
- Amneal Pharmaceuticals, Inc. carries $2.6B in total debt against -$45.4M of shareholders' equity, a debt-to-equity ratio of 127.90.
- How much cash does Amneal Pharmaceuticals, Inc. have?
- Amneal Pharmaceuticals, Inc. holds $197.7M in cash and equivalents.
- Can Amneal Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 2.47 — current assets exceed current liabilities.
- Where does Amneal Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
